Randomized Trial to Test the "Coordinated Care for Health Promotion and Activities in Parkinson's Disease" Intervention in the VA (CHAPS)

March 7, 2019 updated by: VA Office of Research and Development

Improving Quality of Care in Parkinson's Disease: A Randomized Controlled Trial

Health care benefits and services are received through the Veterans Health Administration (VHA), a component of the United States Department of Veterans Affairs. Over 40,000 Veterans across the Veterans Health Administration are diagnosed with Parkinson's disease (PD), a chronic condition that affects motor function as well as cognition, mood, sleep, and autonomic function. There are not enough subspecialists to manage every Veteran with Parkinson's disease. However, a care model of nurse care managers as catalysts and advocates using needs assessments, evidence-based protocols, and VHA and community access coordination mechanisms to optimize Parkinson's disease care may improve quality of Parkinson's disease care and patient-centered outcomes. If efficacious, this model may be practical to disseminate via an existing VHA national consortium network for Parkinson's disease.

Objectives are (1) to implement then analyze via a randomized controlled trial whether a nurse-led, coordinated care management intervention, Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS), compared to usual care will improve adherence to evidence-based practice guidelines and improve health outcomes in Veterans with Parkinson's disease in a region of the southwest United States, and (2) to analyze extent of implementation of the CHAPS intervention and its costs to determine how the intervention can be made sustainable and disseminated throughout Veterans Affairs Medical Centers if efficacious.

Study Overview

Detailed Description

In a 5-year randomized controlled trial, we enrolled 345 Veterans with PD that were then randomized in a 1:1 ratio to receive up to 24 months of a PD care management program, "Care Coordination for Health Promotion and Activities in Parkinson's Disease" (CHAPS), or continue with usual care. Eligible participants across 5 sites of the Southwest Parkinson's Disease Research, Education and Clinical Center (SW PADRECC): Greater Los Angeles, Las Vegas, Loma Linda, Long Beach and San Diego VISN 22 (VA Desert Pacific Healthcare Network) facilities were identified through administrative data and vetted by physicians. The multi-faceted nurse-led intervention, CHAPS, incorporated PD quality improvement (QI) tools to enhance proactive Veteran-centered care delivery. PDQI tools included: (1) a structured telephone assessment administered by a nurse care manager (NCM) to proactively identify medical problems and unmet needs; (2) problem-specific evidence-based interventions organized into treatment plans including follow-up/monitoring protocols with VA and community linkages; (3) the Siebens Domain Management ModelTM, a structural approach to improve collection and organization of health information and enrich communication among providers; (4) Siebens Health Care Notebooks prepared with Veteran self-management materials; (5) a Microsoft Access care management database, containing the CHAPS Assessment and algorithms for problem identification based on Veteran data; and (6) decision-support meetings of NCMs with movement disorder specialists. Research interviewers administer a structured telephone survey at baseline, 6, 12, 18, and 24 months. Participants were provided $25 per survey. Medical records were abstracted.

Ongoing analyses (1) measure PD quality indicator adherence, health outcomes, and health service utilization; (2) evaluate qualitative and quantitative data to summarize the extent of intervention implementation and barriers and facilitators to potential dissemination; and (3) examine costs of CHAPS care and cost offset between randomization arms to provide new knowledge to aid in future dissemination of the CHAPS Program in a "National Rollout" according to the VA Quality Enhancement Research Initiative QUERI process.

Study Type

Interventional

Enrollment (Actual)

345

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Loma Linda, California, United States, 92357
        • VA Loma Linda Healthcare System, Loma Linda, CA
      • Long Beach, California, United States, 90822
        • VA Long Beach Healthcare System, Long Beach, CA
      • San Diego, California, United States, 92161
        • VA San Diego Healthcare System, San Diego, CA
      • West Los Angeles, California, United States, 90073
        • VA Greater Los Angeles Healthcare System, West Los Angeles, CA
    • Nevada
      • Las Vegas, Nevada, United States, 89106
        • VA Southern Nevada Healthcare System, North Las Vegas, NV

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Veteran of the United States of America
  • Receiving health care at one of five Veterans Health Administration medical centers in the southwest United States: Greater Los Angeles, Loma Linda, Long Beach, or San Diego, California, or Las Vegas, Nevada.
  • Diagnosis of Parkinson's disease (PD)
  • At least two ICD-9 diagnostic codes for PD (332.0) in the administrative data from October 1, 2010 - to present date or until recruitment target is met
  • At least 18 years of age
  • Must demonstrate capacity to provide consent for study participation.

Exclusion Criteria:

  • Any Veteran who is a study subject in the Deep Brain Stimulation (DBS) VA cooperative study as these subjects are not to enroll in any other study per DBS study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Usual Care (Arm 1)

Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.

Educational handout: brief educational handout on Parkinson's disease that is available in the VA's "Healthwise for Life" handbook.

Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's "Healthwise for Life" handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise.
Experimental: Intervention (Arm 2)

A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's Disease (PD) by collaborating with these Veterans and their families, providers, and community partners.

Educational handout: brief educational handout on Parkinson's disease that is available in the VA's "Healthwise for Life" handbook.

Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Measures Adhered To in the PD Guidelines
Time Frame: 18 months

Adherence to quality measures for Parkinson's disease care during study period. We operationalized 18 quality measures: 12 were determined through chart review, and 6 were measured using patient survey data.

Range and direction of score: 0 (worst) to 1 (best)

18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health Utilities Index (HUI3)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Range and direction of score: -0.36 (worst) to 1 (best)

18 months
Activities of Daily Living (ADL), (Speech and Swallowing Only)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Range and direction of score: 0 (best) to 16 (worst)

18 months
Medical Outcomes Study (MOS)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Range and direction of score: 1 (worst) to 5 (best)

18 months
General Self-Efficacy Scale (GSES)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Range and direction of score: 10 (worst) to 40 (best)

18 months
Consumer Assessment of Healthcare Providers and Systems (CAHPS)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Range and direction of score: 0 (worst) to 100 (best)

18 months
Patient Assessement of Care for Chronic Conditions (PACIC)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Range and direction of score: 1 (worst) to 5 (best)

18 months
World Health Organization Well-Being Index (WHO-5)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Range and direction of score: 1 (worst) to 25 (best)

18 months
Percentage With a Patient Healthcare Questionnaire-2 (PHQ-2) Score ≥ 3
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

PHQ-2 score ranges from 0 to 4. Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

Higher scores indicate detection of depressive symptoms

18 months
Patient Healthcare Questionnaire-9 (PHQ-9)
Time Frame: 18 months

Data collected at baseline, 6, 12, 18 months. Missing values imputed by last-value carried forward.

Range and direction of score: 0 (best) to 27 (worst). Reported results compared compared data of baseline and final survey results. Additional analyses included repeated-measures models that included data from all time points.

PHQ-9 was only administered to subjects who had a score of 3 or higher on the PHQ-2

18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Karen Connor, PhD RN MBA, VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 9, 2012

Primary Completion (Actual)

January 31, 2017

Study Completion (Actual)

April 30, 2017

Study Registration Dates

First Submitted

January 13, 2012

First Submitted That Met QC Criteria

February 10, 2012

First Posted (Estimate)

February 15, 2012

Study Record Updates

Last Update Posted (Actual)

March 8, 2019

Last Update Submitted That Met QC Criteria

March 7, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Coordinated care management for Parkinson's disease

Subscribe